Key result
Conjugated linoleic acids inhibit vascular inflammatory and vasoactive mediators to exert anti-atherogenic effects.
Answers are grounded in this paper and cite their sources.
Conjugated linoleic acids (CLAs) are biologically highly active lipid compounds that have attracted great scientific interest due to their ability to cause either inhibition of atherosclerotic plaque development or even regression of pre-established atherosclerotic plaques in mice, hamsters and rabbits. The underlying mechanisms of action, however, are only poorly understood. Since cell culture experiments are appropriate to gain insight into the mechanisms of action of a compound, the present review summarizes data from cell culture studies about the metabolism and the actions of CLAs on atherosclerosis-related events in endothelial cells (ECs) and smooth muscle cells (SMCs), which are important cells contributing to atherosclerotic lesion development. Based on these studies, it can be concluded that CLAs exert several beneficial actions including inhibition of inflammatory and vasoactive mediator release from ECs and SMCs, which may help explain the anti-atherogenic effect of CLAs observed in vivo. The observation that significant levels of CLA metabolites, which have been reported to have significant biological activities, are well detectable in ECs and SMCs indicates that the anti-atherogenic effects observed with CLAs are presumably mediated not only by CLAs themselves but also by their metabolites.
No takes yet. Share an insight, caveat, or question.
Eder et al. (2009) conducted a review in Atherosclerosis. Conjugated linoleic acids (CLAs) was evaluated on Inhibition of inflammatory and vasoactive mediator release from endothelial and smooth muscle cells. Conjugated linoleic acids and their metabolites inhibit inflammatory and vasoactive mediator release in endothelial and smooth muscle cell cultures, explaining in vivo anti-atherogenic effects.
Synapse has enriched 10 related papers. Consider them for comparative context: